Details
| Stereochemistry | ABSOLUTE |
| Molecular Formula | C9H15N5O3 |
| Molecular Weight | 241.2471 |
| Optical Activity | UNSPECIFIED |
| Defined Stereocenters | 3 / 3 |
| E/Z Centers | 0 |
| Charge | 0 |
SHOW SMILES / InChI
SMILES
[H][C@@]1(CNC2=C(N1)C(=O)N=C(N)N2)[C@@H](O)[C@H](C)O
InChI
InChIKey=FNKQXYHWGSIFBK-RPDRRWSUSA-N
InChI=1S/C9H15N5O3/c1-3(15)6(16)4-2-11-7-5(12-4)8(17)14-9(10)13-7/h3-4,6,12,15-16H,2H2,1H3,(H4,10,11,13,14,17)/t3-,4+,6-/m0/s1
| Molecular Formula | C9H15N5O3 |
| Molecular Weight | 241.2471 |
| Charge | 0 |
| Count |
|
| Stereochemistry | ABSOLUTE |
| Additional Stereochemistry | No |
| Defined Stereocenters | 3 / 3 |
| E/Z Centers | 0 |
| Optical Activity | UNSPECIFIED |
Approval Year
| Substance Class |
Chemical
Created
by
admin
on
Edited
Sat Dec 16 15:49:48 UTC 2023
by
admin
on
Sat Dec 16 15:49:48 UTC 2023
|
| Record UNII |
EGX657432I
|
| Record Status |
Validated (UNII)
|
| Record Version |
|
-
Download
| Name | Type | Language | ||
|---|---|---|---|---|
|
Official Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Systematic Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Systematic Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Systematic Name | English |
| Classification Tree | Code System | Code | ||
|---|---|---|---|---|
|
LOINC |
59247-7
Created by
admin on Sat Dec 16 15:49:49 UTC 2023 , Edited by admin on Sat Dec 16 15:49:49 UTC 2023
|
||
|
LOINC |
33877-2
Created by
admin on Sat Dec 16 15:49:49 UTC 2023 , Edited by admin on Sat Dec 16 15:49:49 UTC 2023
|
||
|
WHO-ATC |
A16AX07
Created by
admin on Sat Dec 16 15:49:49 UTC 2023 , Edited by admin on Sat Dec 16 15:49:49 UTC 2023
|
||
|
NCI_THESAURUS |
C275
Created by
admin on Sat Dec 16 15:49:49 UTC 2023 , Edited by admin on Sat Dec 16 15:49:49 UTC 2023
|
||
|
WHO-VATC |
QA16AX07
Created by
admin on Sat Dec 16 15:49:49 UTC 2023 , Edited by admin on Sat Dec 16 15:49:49 UTC 2023
|
||
|
NDF-RT |
N0000190483
Created by
admin on Sat Dec 16 15:49:49 UTC 2023 , Edited by admin on Sat Dec 16 15:49:49 UTC 2023
|
||
|
FDA ORPHAN DRUG |
181503
Created by
admin on Sat Dec 16 15:49:49 UTC 2023 , Edited by admin on Sat Dec 16 15:49:49 UTC 2023
|
||
|
EU-Orphan Drug |
EU/3/05/308
Created by
admin on Sat Dec 16 15:49:49 UTC 2023 , Edited by admin on Sat Dec 16 15:49:49 UTC 2023
|
||
|
NCI_THESAURUS |
C1916
Created by
admin on Sat Dec 16 15:49:49 UTC 2023 , Edited by admin on Sat Dec 16 15:49:49 UTC 2023
|
| Code System | Code | Type | Description | ||
|---|---|---|---|---|---|
|
62989-33-7
Created by
admin on Sat Dec 16 15:49:49 UTC 2023 , Edited by admin on Sat Dec 16 15:49:49 UTC 2023
|
PRIMARY | |||
|
Sapropterin
Created by
admin on Sat Dec 16 15:49:49 UTC 2023 , Edited by admin on Sat Dec 16 15:49:49 UTC 2023
|
PRIMARY | |||
|
CHEMBL1201774
Created by
admin on Sat Dec 16 15:49:49 UTC 2023 , Edited by admin on Sat Dec 16 15:49:49 UTC 2023
|
PRIMARY | |||
|
59560
Created by
admin on Sat Dec 16 15:49:49 UTC 2023 , Edited by admin on Sat Dec 16 15:49:49 UTC 2023
|
PRIMARY | |||
|
N0000190482
Created by
admin on Sat Dec 16 15:49:49 UTC 2023 , Edited by admin on Sat Dec 16 15:49:49 UTC 2023
|
PRIMARY | Phenylalanine Hydroxylase Activators [MoA] | ||
|
DB00360
Created by
admin on Sat Dec 16 15:49:49 UTC 2023 , Edited by admin on Sat Dec 16 15:49:49 UTC 2023
|
PRIMARY | |||
|
100000084074
Created by
admin on Sat Dec 16 15:49:49 UTC 2023 , Edited by admin on Sat Dec 16 15:49:49 UTC 2023
|
PRIMARY | |||
|
17528-72-2
Created by
admin on Sat Dec 16 15:49:49 UTC 2023 , Edited by admin on Sat Dec 16 15:49:49 UTC 2023
|
NON-SPECIFIC STEREOCHEMISTRY | |||
|
5276
Created by
admin on Sat Dec 16 15:49:49 UTC 2023 , Edited by admin on Sat Dec 16 15:49:49 UTC 2023
|
PRIMARY | |||
|
EGX657432I
Created by
admin on Sat Dec 16 15:49:49 UTC 2023 , Edited by admin on Sat Dec 16 15:49:49 UTC 2023
|
PRIMARY | |||
|
6553
Created by
admin on Sat Dec 16 15:49:49 UTC 2023 , Edited by admin on Sat Dec 16 15:49:49 UTC 2023
|
PRIMARY | |||
|
TETRAHYDROBIOPTERIN
Created by
admin on Sat Dec 16 15:49:49 UTC 2023 , Edited by admin on Sat Dec 16 15:49:49 UTC 2023
|
PRIMARY | |||
|
C78087
Created by
admin on Sat Dec 16 15:49:49 UTC 2023 , Edited by admin on Sat Dec 16 15:49:49 UTC 2023
|
PRIMARY | |||
|
753340
Created by
admin on Sat Dec 16 15:49:49 UTC 2023 , Edited by admin on Sat Dec 16 15:49:49 UTC 2023
|
PRIMARY | RxNorm | ||
|
N0000190113
Created by
admin on Sat Dec 16 15:49:49 UTC 2023 , Edited by admin on Sat Dec 16 15:49:49 UTC 2023
|
PRIMARY | Breast Cancer Resistance Protein Inhibitors [MoA] | ||
|
DTXSID1041138
Created by
admin on Sat Dec 16 15:49:49 UTC 2023 , Edited by admin on Sat Dec 16 15:49:49 UTC 2023
|
PRIMARY | |||
|
135398654
Created by
admin on Sat Dec 16 15:49:49 UTC 2023 , Edited by admin on Sat Dec 16 15:49:49 UTC 2023
|
PRIMARY | |||
|
SUB10445MIG
Created by
admin on Sat Dec 16 15:49:49 UTC 2023 , Edited by admin on Sat Dec 16 15:49:49 UTC 2023
|
PRIMARY | |||
|
27070-47-9
Created by
admin on Sat Dec 16 15:49:49 UTC 2023 , Edited by admin on Sat Dec 16 15:49:49 UTC 2023
|
ALTERNATIVE | |||
|
15372
Created by
admin on Sat Dec 16 15:49:49 UTC 2023 , Edited by admin on Sat Dec 16 15:49:49 UTC 2023
|
PRIMARY | |||
|
m9775
Created by
admin on Sat Dec 16 15:49:49 UTC 2023 , Edited by admin on Sat Dec 16 15:49:49 UTC 2023
|
PRIMARY | Merck Index | ||
|
N0000185503
Created by
admin on Sat Dec 16 15:49:49 UTC 2023 , Edited by admin on Sat Dec 16 15:49:49 UTC 2023
|
PRIMARY | P-Glycoprotein Inhibitors [MoA] | ||
|
2612
Created by
admin on Sat Dec 16 15:49:49 UTC 2023 , Edited by admin on Sat Dec 16 15:49:49 UTC 2023
|
PRIMARY | |||
|
EGX657432I
Created by
admin on Sat Dec 16 15:49:49 UTC 2023 , Edited by admin on Sat Dec 16 15:49:49 UTC 2023
|
PRIMARY |
| Related Record | Type | Details | ||
|---|---|---|---|---|
|
|
SALT/SOLVATE -> PARENT | |||
|
|
SALT/SOLVATE -> PARENT |
| Related Record | Type | Details | ||
|---|---|---|---|---|
|
|
ACTIVE MOIETY |
| Name | Property Type | Amount | Referenced Substance | Defining | Parameters | References |
|---|---|---|---|---|---|---|
| Biological Half-life | ENZYMATIC |
|
ORAL ADMINISTRATION |
|
||
| Tmax | ENZYMATIC |
|
ORAL ADMINISTRATION |
|
||